Skip to Content

LAG3 Inhibitors Change The Landscape Of Immunotherapy

A new immunotherapy checkpoint inhibitor targeting LAG3, relatlimab, shows promising results when given as a fixed-dose combination with the PD-1 inhibitor nivolumab for the treatment of metastatic melanoma in patients with low PD-L1 expression.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top